-+ 0.00%
-+ 0.00%
-+ 0.00%

Q32 Bio to release 36-week SIGNAL-AA Phase 2a bempikibart data July 13

PUBT·07/10/2026 20:06:11
Listen to the news
Q32 Bio to release 36-week SIGNAL-AA Phase 2a bempikibart data July 13
  • Q32 Bio will release 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe alopecia areata on July 13, 2026.
  • A conference call and webcast to discuss the data is scheduled for 8:00 a.m. ET that day.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607101605PR_NEWS_USPR_____NE02074) on July 10, 2026, and is solely responsible for the information contained therein.